Integrated Care 24
Annual Report and Financial Statements
For the year ended 30 June 2024
Company Registration No. 03193182 (England and Wales)
Integrated Care 24
Company Information
Directors
A Catto
A Karki
A Oag
D Brown
D R Baines
K Gentleman
K Pitts
P Brooke
(Appointed 31 July 2023)
R Robinson
S P King
Company number
03193182
Registered office
Kingston House
Orbital Park
Ashford
Kent
TN24 0GP
Auditor
Moore Kingston Smith LLP
6th Floor
9 Appold Street
London
EC2A 2AP
Integrated Care 24
Contents
Page
Strategic report
1 - 5
Directors' report
6 - 10
Independent auditor's report
11 - 14
Consolidated statement of total comprehensive income
15
Group balance sheet
16
Company balance sheet
17
Group statement of changes in equity
18
Company statement of changes in equity
19
Consolidated statement of cash flows
20
Notes to the financial statements
21 - 45
Integrated Care 24
Strategic Report
For the year ended 30 June 2024
Page 1

The Directors present their report and financial statements for the year ended 30 June 2024.

Fair review of the business

We are a not-for-profit social enterprise whose purpose is to enable health systems to improve patient experience of urgent care. We have no shareholders, and any surplus funds are re-invested into improving care delivery and social value.

 

IC24 provides integrated urgent care services across a population of some 6.3 million people in South and East England, including NHS 111, urgent primary care, and related healthcare services. In addition we provide General Medical Services (GMS) Primary care in Sussex and supply ICT systems to support other organisations through our CLEO systems subsidiary.

 

This report reflects on the organisation's performance, challenges, and key strategic initiatives for the year.

 

The financial year 2023/24 has been marked by both ongoing challenges and significant progress for IC24. While the healthcare sector continues to navigate the aftermath of the COVID-19 pandemic, with pressures on urgent and emergency care services, IC24 has remained agile in adapting to changing needs. This year has seen the ongoing evolution of our service offering, with expanded roles in primary care, digital health, and out-of-hours services. However, the principal activity of the social enterprise continues to be that of providing unscheduled urgent integrated care (NHS111 and urgent primary care). In addition, IC24 also provides in-hours primary care to patients in 3 practices in Brighton and our subsidiary, CLEO Systems, continues to show steady growth in the digital healthcare space, particularly with its electronic prescribing solution.

 

Our social enterprise owns 100% of the issued share capital of Brightdoc 24 Limited, which provides locum doctors to the organisation and 50% of the issued share capital of iDental Care 24 Ltd which provides out of hours dental care in Brighton.

 

In February 2024 IC24 sold its 100% shareholding in Pharma Alert 24 Limited, which operates a pharmacy in Hastings. During the year commissioners in both Norfolk and Waveney and Mid & South Essex expressed their intention to award IC24 new contracts which enables us to continue to invest and innovate to better support patients and partners. Norfolk awarded the new contract in August 2024 and discussions are progressing well with Mid and South Essex.

 

We continue to provide the unique, national NHS paediatric clinical assessment service (PCAS) which was initiated in August 2021 to support parents with unwell children. This continues to be an exemplar of providing senior opinion at an early stage in the patient pathway. This service contract was extended during the year and the service was provided for the whole of 2023/24.

 

In late 2023 NHS England took the decision to end the National Service Advisor resilience service, which meant sadly saying goodbye to some of the colleagues involved in February 2024 as we closed it down.

 

IC24 continued to operate several smaller contracts in Sussex, including a home visiting service, roving GP service, emergency department primary care service and overnight district nursing service. The latter two services were decommissioned during 2023/24 as Sussex commissioners sought to reduce their costs.

 

CLEO Systems 24 Ltd is a wholly owned subsidiary of IC24. CLEO Systems is a leading developer and integrator of digital solutions for primary, secondary, urgent and emergency care markets and has continued to evolve and grow in this financial year. CLEO Systems is committed to improving the experience of patients using Integrated Urgent Care (IUC) services and the most notable impact was the development and marketing of an NHS electronic prescribing solution (EPS).

Integrated Care 24
Strategic Report (Continued)
For the year ended 30 June 2024
Page 2
Our Development and Performance
Financial performance

For the year ending 30 June 2024, IC24 has faced a challenging financial environment, with high inflation and rising operational costs driven by increases in the national living wage not being fully covered by commissioners. We have had to work extra hard on improving productivity to ensure we remained financially stable. In addition we have invested more than £600k in Primary care in the three practices we acquired the contract to run in Brighton, to ensure we improved the service provision to patients and as part of our wider strategy.

 

Revenue for the year remained stable at £75 million, with an increase of £2 million compared to the previous year, primarily driven by the provision of the new care home support and the Covid Medicines Delivery Unit (CMDU) in Norfolk, expansion of our primary care services, the full year effect of our national resilience and Paediatric CAS contracts. Meanwhile, turnover growth has been limited by the loss of contracts such as Home Nursing and emergency GP’s in Sussex and the sale of the Pharma Alert pharmacy which sadly could not be made to cover its costs. In addition, 111 income was impacted by reductions in funding of the service by Essex commissioners as they try to reduce costs.

 

The surplus for the year after taxation was £1.0 million, down from £4.1 million in 2023, reflecting the pressures of increasing staffing and operational costs. Nevertheless, the Directors are confident that IC24 remains financially robust and well-positioned to meet future challenges.

 

 

Current Operating Position Including Key Performance Indicators

IC24 provides 111 services directly to Norfolk and Essex commissioners along with being part of a joint venture with South East Coast Ambulance Service (SECAmb) for Kent and Sussex. In total IC24 is responsible for 4.9% of total NHS 111 Call Volume: IC24 answered 926,780 111 calls in 2023/24, which represented a 5% increase over the prior year. In addition, our performance in terms of percentage of calls answered in sixty seconds, which struggled in 2022/23 (49.8% on average) improved significantly to 74.3% and has continued to improve in the early part of 2024/25. Nationally, demand into 111 has increased 11.6% in 2023/24 as rapid access to Primary and secondary care health provision has become harder to access.

 

In addition, IC24 ran the temporary National Call answering service until the end of February 2024. This service diverted simpler calls from National 111. We answered 327,723 calls during 2023/24 reducing pressure on National 111 by 1.7%.

 

We continue to provide the virtual Clinical Assessment Service (CAS) in Norfolk, Essex, and, along with our partner SECAmb in Kent. The number of patients we were able to advise in 2023/24 was 130,410 which would otherwise need to have been seen by other parts of the NHS such as GPs.

 

National Health Service England have also extended the Paediatric Clinical Assessment Service (PCAS) where we are the single national provider. This service answers calls from all 111 providers in relation to children by using specialist Paediatricians and Childrens Advanced Nurses Practitioners. Of the 35,002 calls received, 60% were resolved through self-care advice, avoiding unnecessary trips to A&E, GP’s and significantly improving patient outcomes.

 

This year we have focused on the operational effectiveness of our out of hours and home visiting service across Norfolk, Essex, Kent and Sussex. With the end of COVID we have seen a 33% increase in patient contacts via these services, mainly in base visits. We visited 35,807 patients at home and undertook 589,197 patient appointments in local bases and issued 128,636 prescriptions.

Integrated Care 24
Strategic Report (Continued)
For the year ended 30 June 2024
Page 3

Our work is aimed at reducing the number of downstream dispositions to statutory ambulance and acute trust providers. A key operational priority is ensuring that IC24 minimises the impact of urgent care demand on the systems in which we work. During 2023/24 we clinically reviewed 46,823 of the 111 calls that initially indicated an emergency referral to hospital was required resulting in 26,177 patients appropriately diverted to a more suitable service, and thus reducing the load on hospital emergency services. In addition, we also reviewed 116,032 of the 111 calls that initially indicated an Ambulance was required to visit. This review resulted in 66,273 fewer patients requiring ambulance visits. These reviews are critical to ensure ambulances and hospitals are free to focus on the most appropriate patients.

 

IC24’s acquisition of the contract to run three GP practices in Sussex expanded our reach in primary care, enabling us to serve over 14,000 patients. This aligns with NHS strategic priorities, notably those outlined in the Fuller Report, which advocates for greater integration between urgent and primary care services to improve patient experience and clinical outcomes. We have worked with these practices to standardise their back office functions, provide remote consultations where effective and focus on improving their quality and range of services to patients. Whilst doing this the organisation has made a net investment of more than £0.6 million in staff and improving facilities to ensure patients receive a positive primary care service.

 

Another regional system collaboration initiative this year has been the launch of our Covid Medicines Delivery Unit (CMDU) in Norfolk. This service was mobilised to ensure clinically vulnerable patients who test positive for covid19 are triaged and assessed for eligibility of antiviral medication. These patients require detailed clinical assessment and prescribing. Bespoke training packages and pathways were developed for our clinicians. This centralised service has also enabled our system partners in primary care to signpost eligible patients into our service to support capacity.

 

CLEO Systems, a subsidiary of IC24, remains at the forefront of digital healthcare innovation. The development of the CLEO SOLO electronic prescribing system (EPS) has seen successful pilots in partnership with NHS Trusts, including Midlands Partnership NHS Foundation Trust. This EPS solution has recently been commissioned by NHS for 180 pharmacies across England. As part of our digital health strategy, CLEO is well-positioned to support the digital transformation of urgent and emergency care, with a growing pipeline of contracts in development.

 

 

Our People

By making IC24 a great place to work for our people, we can continue to deliver exceptional care to our patients. We know that a happy and engaged workforce delivers better patient outcomes.

 

We use our annual engagement survey and various specific questionnaires throughout the year to identify opportunities to make IC24 a better place to work. This year we invited colleagues to join our employee voice forum, Link 24 and we launched our Employee Alliance and regional Listening into Action sessions so that we could hear directly from our colleagues about what matters most to them. Hearing feedback directly from our workforce is vital for our continued organisational growth, which not only includes recruiting top talent but retaining and development our current workforce.

Integrated Care 24
Strategic Report (Continued)
For the year ended 30 June 2024
Page 4

Well-being is one of eight factors in our annual engagement survey and our overall score of employee wellbeing has increased each year.

 

The health and wellbeing at work of our employees is our highest priority and we are always looking for ways we can enhance the support we provide to deliver a range of initiatives our people find helpful.

 

Supporting the mental health at work of our people has been a key area of this year which saw us partner with Able Futures who deliver a comprehensive mental health support service for employees. We have continued to invest in the Mind Health Journey and since we commenced this initiative, over 200 colleagues have registered to take part. We have also provided mental health training for Managers to support their teams and we incorporated wellbeing into our Leadership Development Programme.

 

 

Equality, diversity, and inclusion

Our four Colleague Resource Groups (CRG) continue to provide our employees with a voice to celebrate diversity, promote inclusivity, equity and diversity. Through our CRGs we provide a safe space to voice issues, promote allyship and provide education and support for people in the spaces of cultural inclusion, disability, gender equality and LGBTQ+.

 

In May we launched our annual inclusion and belonging survey which forms part of the NHS Workforce Race Equality Standard (WRES) and Workforce Disability Standard (WDES) campaigns which enables us to monitor our progress against indicators of workforce equality. We have seen a sustained increase in response rate over recent years from 18% of workforce in 2022 to 26% of workforce in 2023.

 

IC24 was proud to be recognised in several “Best Places to Work” lists, reflecting our focus on creating an inclusive and supportive work environment. We also continue to make significant progress in advancing our equality, diversity, and inclusion (EDI) agenda, with notable achievements such as the signing of the NHS England Sexual Safety in Healthcare Charter and progress towards becoming a Level 3 Disability Confident Leader.

 

 

Sustainability and environmental impact

At IC24 we take our environmental responsibilities seriously. We understand the importance of the environment and the need to manage energy use and waste to ensure our impact on the environment and climate change is reduced as far as is reasonably practicable. We are UKAS accredited to ISO 14001:2015 and undergo regular review by an external third-party to ensure our environmental credentials are continuously improved. As a major healthcare provider and supplier of healthcare services to the NHS, we have a Board approved Sustainable Development Management Action Plan in place.

 

By embracing sustainability and mitigating harmful practices, we are creating social value through the protection of the environment. Environmental considerations are about the contribution and extent to which we are minimising our negative impact, including supporting local activities that seek to protect the local environment from waste and pollutants. One practical example of this is the introduction of thirty four hybrid vehicles in our home visiting service to replace older diesel models.

Integrated Care 24
Strategic Report (Continued)
For the year ended 30 June 2024
Page 5
Principal risks and uncertainties

IC24 faces several risks that could impact our ability to deliver on our mission. These include:

 

Financial Sustainability: Inflation and rising staff costs continue to be a challenge, as NHS contracts have not always kept pace with the increasing cost base. We are working closely with commissioners to manage these pressures and have workstreams to focus on, and deliver, efficiencies in our services to ensure that services remain financially sustainable.

 

Workforce Capacity: The ability to recruit and retain skilled staff, particularly clinical personnel, is an ongoing challenge. Our “Great Place to Work” strategy continues to be our primary mitigation, alongside investment in workforce development and flexible working arrangements.

 

Changing Healthcare Landscape: The reorganisation of the NHS into Integrated Care Systems (ICS) presents both risks and opportunities. The future of large-scale Integrated Urgent Care (IUC) contracts remains uncertain, but we continue to explore new partnerships to ensure our long-term viability as demonstrated by our joint ventures with SECAmb and, more recently with Gloucestershire Health and Care NHS Foundation Trust.

 

Digital Transformation: As CLEO Systems grows, the risk of managing significant expansion while maintaining high-quality customer support is a key focus. We are continuing to invest in infrastructure and governance to support this growth.

 

 

Conclusion and looking ahead

IC24 remains committed to its purpose of improving patient care and experience through the provision of high-quality, integrated urgent care services. Despite the ongoing challenges in the healthcare sector, we are confident that our strategic focus on primary care integration, digital health innovation, and workforce development will position us well for the future. Our focus on our core values of Patients, People, and Partners will ensure that we continue to meet the evolving needs of the NHS and the communities we serve. We will also continue to ensure efficiency and effectiveness are key to our future in order that we continue to run both a financially stable and environmentally responsible organisation.

 

On behalf of the board

Dr Andrew Catto PhD FRCP
Chief Executive Officer
16 December 2024
Integrated Care 24
Directors' Report
For the year ended 30 June 2024
Page 6

The directors present their report and financial statements for the year ended 30 June 2024.

 

In accordance with s414c(11) of the Companies Act 2006, the information relating to future developments and financial risk management are included in the Strategic Report.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

A Catto
A Karki
A Oag
D Brown
D R Baines
K Gentleman
K Pitts
P Brooke
(Appointed 31 July 2023)
R Robinson
S P King
D L Supple
(Resigned 31 July 2023)
K Eldridge
(Resigned 28 February 2024)
R T McEwan
(Resigned 30 June 2024)
Financial Results

The results for the year are set out on page 15.

Our Social Purpose

We are an NHS Social Enterprise. We do not distribute profits to shareholders but invest any surplus funds to improve NHS health systems and services. The purpose of IC24 is to improve the experience of people seeking urgent care and primary care.

What we do

We are the leading Social Enterprise providing Integrated Urgent Care to patients 24/7 in the South East and East of England. We deploy our values of innovation, care, excellence and respect to improve patient’s experience of urgent and Primary care. In particular we use our technological expertise to improve health system services by developing innovative IT systems and solutions that improve patient safety and quality as well as organisational efficiency.

Integrated Care 24
Directors' Report (Continued)
For the year ended 30 June 2024
Page 7
Statement by the directors relating to their statutory duties under section 172(1) of the Companies Act 2006

The directors, in line with their duties under s172 of the Companies Act 2006, act individually and collectively in the way they consider, in good faith, would be most likely to promote the success of the group for the benefit of its stakeholders, and in doing so have regard, amongst other matters, to the:

 

Stakeholders

The board understands the importance of engagement with all of its stakeholders and gives appropriate weighting to the outcome of its decisions for the relevant stakeholder in weighing up how best to promote the success of the group. The board regularly discusses issues concerning partners, suppliers, employees, community and environment, regulators and its members, which it takes into account in its discussions and in its decision-making process. In addition to this, the board seeks to understand the interests and views of the group's stakeholders by engaging with them directly when required. The below summarises the key stakeholders and how we engage with each:

Working with partners

We work in some formal and many informal partnerships. Our key skill is helping integrate work between partners. We work closely with NHS GP services to help them manage their patients' urgent care needs, ambulance services and accident and emergency services to reduce the numbers of people who use their scarce resources unnecessarily and of course, NHS commissioners and many other NHS providers to improve patient safety and experience. We are grateful to commissioners for entrusting us with the Primary Care needs of the populations for whom they are responsible.

Suppliers
We work with a range of suppliers to ensure we create sustainable, long-term relationships utilising other social enterprises where practical. The Group has, where relevant, procedures in place requiring due diligence of suppliers as to their internal governance, including for example, their anti-bribery and corruption practices, data protection policies and modern slavery matters. The group has systems and processes in place to ensure suppliers are paid in a timely manner.
Commitment to Quality and Safety
Our overriding priority is to ensure the safety of the public, patients and our people and the quality of service people experience from us. We aim to embed a quality and safety culture, with a network of quality champions, systematic clinical oversight and an enquiring and open approach to investigating incidents so we can learn from them. CQC inspections of our services have rated us as “Good”. We play our part in the “Greener NHS programme as part of the wider NHS commitment to achieve net zero by 2050.
Freedom to Speak Up
We also know sometimes things go wrong. So, we encourage our people to “Speak Up” when they see something that they do not think is right.  We have an appointed “Freedom to speak up” guardian whose role is to ensure people are heard, and FTSU champions to encourage and support people to speak up. We encourage colleagues to come forward as part of our open and honest culture so we can look into the concern and determine what, if any, changes need to be made as a result.
Integrated Care 24
Directors' Report (Continued)
For the year ended 30 June 2024
Page 8
Employee involvement and inclusion
We want to be a great place to work for everyone. We aim to go far beyond our statutory requirements to inform and consult with colleagues, and make sure everyone feels included. We have developed a range of channels and work groups to help colleagues understand their role and feel included in the organisation, and most importantly, to harness their ideas for improving our services. We understand that involved and engaged people are at the heart of delivering the quality we strive for. We have specific groups to help ensure we have active staff engagement and participation in areas which impact them the most.
Commitment to people with disabilities
One in five working-age adults reports having a disability. We are positive about harnessing the skills and talents of people who have disabilities as colleagues in our teams. IC24 are a Disability Confident ‘Committed' employer.  We carry the Disability Confident badge to show disabled people that we recognise the value they can bring to our business and are working towards disability confident level 2.
Diversity and inclusion
We have engaged in a listening programme and initiated a number of colleague forums to enable the organisation to listen to and encourage the participation of diverse colleagues in our business. Our aim is to ensure our organisation is not only open to all colleagues but provides equity and equality of opportunity within our working environment.
Reducing our Environmental impact
We take our environmental responsibilities seriously. We understand the importance of the environment and the need to manage energy use and waste to ensure our impact on the environment and climate change is reduced “as far as is reasonably practicable”.

To comply with the requirements of the Governments Energy Savings Opportunity Scheme (ESOS), We record energy use throughout our organisation, where it is possible to measure it. Due to the nature of some of the locations where we operate, we are not always in a position to measure energy use, for example in hospitals and clinics.

To gather the relevant information, invoices/utility bills have been used to collect usage figures. Regional offices record monthly meter readings to help identify usage issues early and to enable more frequent actual meter readings to be provided to the suppliers.
The table below shows the main resources used by the Group and the associated greenhouse emissions.
Integrated Care 24
Directors' Report (Continued)
For the year ended 30 June 2024
Page 9
Y/E 2023/24
Y/E 2022/23 (as restated)
Difference (greenhouse gas emissions)
Utility
Recorded Usage
Associated Greenhouse Emissions (Kgs) (CO2e)
Recorded Usage
Associated Greenhouse Emissions (Kgs) (CO2e)
Kg
% Movement
Electricity
891,823 KWh
184,673
892,134 KWh
172,521
12,152
7%
Gas
433,362 KWh
80,369
313,183 KWh
57,512
22,857
40%
Vehicle fuel
53,817 L
135,612
549,408 L
144,468
(8,856)
-6%
Water
5,112 cubic metres
965
4,051 cubic metres
846
119
14%
Biomass space heating
12 biomass wooden pellets (Tonnes)
584
7.0 biomass wooden pellets (Tonnes)
354
230
65%
Refrigerant gases
-
-
-
-
-
Total emissions
402,203
375,701
26,502
7%
FTE Employees
658
653
Co2e per FTE
611
575
N.B. please note prior year electricity readings have been restated to take account of the fact that part of the Reed House premises is sub contracted to another organisation. The figures for both years are therefore now better reflective of IC24 usage and comparable year on year. Based on FTE's the CO2 usage is estimated to be equivalent to 611Kg CO2e per FTE Employee based on 2023/24 in which we had an average of 611 WTE's. This is 6.2% higher than the prior year. In addition it should be noted that that we do not have any 2022/23 figures for the Primary Care practice buildings as we did not control these throughout 2022/23 and have been unable to get some data from our Landlord in Hastings.
The UK Government provides an annual document - Greenhouse Gas Factors (GGF) for Company Reporting. This document enables organisations to convert energy use or waste figures into equivalent greenhouse gas emissions, thus enabling organisations to measure its impact on the environment and climate change. For this report we have used 2023 factors for the year 2023/24 and the 2022 factors for 2022/23.
The level of CO2 from electricity use has increased by 7% but this is mainly due to the increase in GGF as different fossil fuels have been used to generate electricity in the UK.  Ignoring this factor and the additional Primary Care practices our CO2 emissions fell slightly due to work on more efficient lighting particularly in Reed House.

Gas CO2 increased 40% and Biomass 65% in year. This is entirely driven by the Primary Care sites where limited prior year data is available and Hastings where we have limited data from the landlord.

Our use of vehicle fuel fell mainly driven by the introduction of newer hybrid cars improving consumption.
An environmental news-letter is distributed to all staff to raise awareness of energy usage, and we have particularly focused on our drivers, as vehicle fuel is a large source of CO2 emissions.  In order to reduce the carbon footprint of our Home Visiting services we continued investing in more hybrid cars this year and are keeping further options under review as technology improves in order that we can contribute to the NHS drive to carbon neutrality. In line with NHS requirement we have now created a environmental long term strategy.
Integrated Care 24
Directors' Report (Continued)
For the year ended 30 June 2024
Page 10
Auditor

The auditors, Moore Kingston Smith LLP, are deemed to be reappointed under section 487(2) of the Companies Act 2006.

Statement of directors' responsibilities

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the surplus or deficit of the group for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

 

On behalf of the board
A Catto
Director
16 December 2024
Integrated Care 24
Independent Auditor's Report
To the Members of Integrated Care 24
Page 11
Opinion

We have audited the financial statements of Integrated Care 24 (the 'parent company') and its subsidiaries (the 'group') for the year ended 30 June 2024 which comprise the Consolidated Statement of Total Comprehensive Income, the Group Balance Sheet, the Company Balance Sheet, the Group Statement of Changes in Equity, the Company Statement of Changes in Equity, the Consolidated Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

 

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Integrated Care 24
Independent Auditor's Report (Continued)
To the Members of Integrated Care 24
Page 12

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Directors' Report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

 

In preparing the financial statements, the directors are responsible for assessing the group's and parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or parent company or to cease operations, or have no realistic alternative but to do so.

Integrated Care 24
Independent Auditor's Report (Continued)
To the Members of Integrated Care 24
Page 13
Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

 

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

 

Integrated Care 24
Independent Auditor's Report (Continued)
To the Members of Integrated Care 24
Page 14

Explanation as to what extent the audit was considered capable of detecting irregularities, including

fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities,

including fraud is detailed below.

 

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the company.

 

Our approach was as follows:

Ÿ

 

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken for no purpose other than to draw to the attention of the company’s members those matters we are required to include in an auditor's report addressed to them. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Robert Kersse (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP
19 December 2024
Chartered Accountants
Statutory Auditor
6th Floor
9 Appold Street
London
EC2A 2AP
Integrated Care 24
Consolidated Statement of Total Comprehensive Income
For the year ended 30 June 2024
Page 15
2024
2023
Notes
£
£
Income
3
74,971,156
73,033,706
Cost of sales
(62,556,868)
(58,736,587)
Gross surplus
12,414,288
14,297,119
Administrative expenses
(12,404,541)
(10,020,345)
Other operating income
3
147,934
195,914
Operating surplus
4
157,681
4,472,688
Income from interests in associated undertakings
8
118,302
121,317
Other interest receivable and similar income
8
843,222
384,115
Interest payable and similar expenses
9
(3,291)
(134)
Profit on disposal of subsidiary
14
200,000
-
Surplus on ordinary activities before taxation
1,315,914
4,977,986
Tax on surplus on ordinary activities
10
(273,067)
(829,181)
Surplus on ordinary activities after taxation and total comprehensive income
1,042,847
4,148,805
Total comprehensive income for the year is all attributable to the members of the parent company. There were no amounts of other comprehensive income in the current or prior year.

The consolidated statement of total comprehensive income has been prepared on the basis that all operations are continuing operations.

 

 

Integrated Care 24
Group Balance Sheet
As at 30 June 2024
30 June 2024
Page 16
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
11
206,404
277,771
Tangible assets
12
2,957,614
2,494,632
Investments
13
177,931
159,629
3,341,949
2,932,032
Current assets
Stocks
16
-
104,168
Debtors
17
6,331,046
11,259,561
Cash at bank and in hand
20,779,771
16,675,307
27,110,817
28,039,036
Creditors: amounts falling due within one year
18
(7,868,117)
(9,310,957)
Net current assets
19,242,700
18,728,079
Total assets less current liabilities
22,584,649
21,660,111
Creditors: amounts falling due after more than one year
19
(27,487)
(129,162)
Provisions for liabilities
21 & 23
(953,270)
(969,904)
21,603,892
20,561,045
Capital and reserves
Merger reserve
1,043,841
1,043,841
Income and expenditure account
20,560,051
19,517,204
Shareholders' funds
21,603,892
20,561,045
The financial statements were approved by the board of directors and authorised for issue on 16 December 2024 and are signed on its behalf by:
16 December 2024
D R Baines
A Catto
Chief Executive Officer
Director
Integrated Care 24
Company Balance Sheet
As at 30 June 2024
30 June 2024
Page 17
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
11
196,345
262,346
Tangible assets
12
2,928,768
2,480,840
Investments
13
620
620
3,125,733
2,743,806
Current assets
Debtors
17
7,115,357
11,390,677
Cash at bank and in hand
20,000,406
16,044,940
27,115,763
27,435,617
Creditors: amounts falling due within one year
18
(7,569,271)
(9,364,295)
Net current assets
19,546,492
18,071,322
Total assets less current liabilities
22,672,225
20,815,128
Creditors: amounts falling due after more than one year
19
(27,487)
(129,162)
Provisions for liabilities
21 & 23
(953,270)
(969,904)
Net assets
21,691,468
19,716,062
Capital and reserves
Merger reserve
1,043,841
1,043,841
Income and expenditure account
20,647,627
18,672,221
Total equity
21,691,468
19,716,062

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £1,975,406 (2023 - £4,376,251 profit).

The financial statements were approved by the board of directors and authorised for issue on 16 December 2024 and are signed on its behalf by:
16 December 2024
D R Baines
A Catto
Chief Executive Officer
Director
Company Registration No. 03193182
Integrated Care 24
Group Statement of Changes in Equity
For the year ended 30 June 2024
Page 18
Merger reserve
Income and expenditure account
Total
£
£
£
Balance at 1 July 2022
1,043,841
15,368,399
16,412,240
Year ended 30 June 2023:
Surplus and total comprehensive income for the year
-
4,148,805
4,148,805
Balance at 30 June 2023
1,043,841
19,517,204
20,561,045
Year ended 30 June 2024:
Surplus and total comprehensive income for the year
-
1,042,847
1,042,847
Balance at 30 June 2024
1,043,841
20,560,051
21,603,892
Integrated Care 24
Company Statement of Changes in Equity
For the year ended 30 June 2024
Page 19
Merger reserve
Income and expenditure account
Total
£
£
£
Balance at 1 July 2022
1,043,841
14,295,970
15,339,811
Year ended 30 June 2023:
Surplus and total comprehensive income for the year
-
4,376,251
4,376,251
Balance at 30 June 2023
1,043,841
18,672,221
19,716,062
Year ended 30 June 2024:
Surplus and total comprehensive income for the year
-
1,975,406
1,975,406
Balance at 30 June 2024
1,043,841
20,647,627
21,691,468
Integrated Care 24
Group Statement of Cash Flows
For the year ended 30 June 2024
Page 20
2024
2023
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
27
4,819,743
4,144,936
Interest paid
(3,291)
(134)
Income taxes paid
(409,000)
(1,729,295)
Net cash inflow from operating activities
4,407,452
2,415,507
Investing activities
Purchase of intangible assets
(73,463)
(38,303)
Purchase of tangible fixed assets
(1,381,607)
(1,380,983)
Proceeds from disposal of tangible fixed assets
49,336
33,505
Cash dividend from associate
100,000
125,000
Proceeds from disposal of subsidiary
200,000
-
Interest received
832,389
378,280
Net cash used in investing activities
(273,345)
(882,501)
Financing activities
Payment of finance leases obligations
(29,643)
(118,572)
Net cash used in financing activities
(29,643)
(118,572)
Net increase in cash and cash equivalents
4,104,464
1,414,434
Cash and cash equivalents at beginning of year
16,675,307
15,260,873
Cash and cash equivalents at end of year
20,779,771
16,675,307
Integrated Care 24
Notes to the Financial Statements
For the year ended 30 June 2024
Page 21
1
Accounting policies
Company information

Integrated Care 24 (“the Company”) is a company limited by guarantee which is domiciled and incorporated in England and Wales. The registered office is Kingston House, Orbital Park, Ashford, Kent, TN24 0GP.

 

The Group consists of the company and all its subsidiaries, as listed on page 38.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest pound.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and surplus or deficit of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:

 

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £1,975,406 (2023 - £4,376,251 profit).

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
1
Accounting policies
(Continued)
Page 22
1.2
Basis of consolidation

The consolidated financial statements incorporate those of the company and all of its subsidiaries (i.e. entities that the Group controls through its power to govern the financial and operating policies so as to obtain economic benefits). Subsidiaries acquired during the year are consolidated using the purchase method. Their results are incorporated from the date that control passes. All financial statements are made up to 30 June 2024.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation.

 

The cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill.

 

Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date.

Entities in which the group holds an interest and which are jointly controlled by the group and one or more other venturers under a contractual arrangement are treated as joint ventures. Entities other than subsidiary undertakings or joint ventures, in which the group has a participating interest and over whose operating and financial policies the group exercises a significant influence, are treated as associates.

Investments in joint ventures and associates are carried in the group balance sheet at cost plus post-acquisition changes in the group’s share of the net assets of the entity, less any impairment in value. The carrying values of investments in joint ventures and associates include acquired goodwill.

 

If the group’s share of losses in a joint venture or associate equals or exceeds its investment in the joint venture or associate, the group does not recognise further losses unless it has incurred obligations to do so or has made payments on behalf of the joint venture or associate.

 

Unrealised gains arising from transactions with joint ventures and associates are eliminated to the extent of the group’s interest in the entity.

1.3
Going concern

In the opinion of the directors the group is a going concern with sufficient liquidity to cope with the current and expected future trading environment. In addition, the group continues to perform satisfactorily, despite the challenging conditions created by the current economic environment, and has sufficient financial resources to meet operational requirements.

 

The directors have based this assessment on forecasts showing the group’s expected financial position over the next twelve months from the date of signing these financial statements and considering the group’s cash reserves and net assets at June 2024. The company also has a number of contracts in place with Integrated Care Boards in four different counties which extend beyond this period.

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
1
Accounting policies
(Continued)
Page 23
1.4
Income

Income represents amounts receivable for the provision of out of hours services and NHS 111 service and associated services net of VAT. Income is recognised in the period in which the services are performed in line with the underlying contract.

 

Income received in respect of government grants has been recognised on the accruals basis in line with the recognition criteria outlined in section 24 of FRS 102. Where the income relates to capital grants, the income is recognised over the useful life of the assets to which the funding relates and where the funding relates to non-capital grants, this is recognised in the period where the expenditure to which it relates is incurred.

1.5
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
5 years straight line
Development Costs
3 years straight line

Amortisation of intangible fixed assets is included in administrative expenses.

1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Land and buildings Leasehold
Over the period of the lease
Fixtures, fittings & equipment
15% to 33% straight line
Motor vehicles
15% straight line
Medical equipment
33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the income and expenditure account.

Where assets are used exclusively for a particular contract, the asset will be depreciated over the duration of the contract. This may result in change in depreciation policy if contracts are extended.

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
1
Accounting policies
(Continued)
Page 24
1.7
Fixed asset investments

Equity instruments are measured at fair value through surplus or deficit except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably which are recognised at cost less impairment until a reliable measure of fair value becomes available.

In the parent company financial statements investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The group considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

 

Investments in associates are initially recognised at the transaction price (including transaction costs) and are subsequently adjusted to reflect the group’s share of the surplus or deficit, other comprehensive income and equity of the associate using the equity method.

 

Any difference between the cost of acquisition and the share of the fair value of the net identifiable assets of the associate on acquisition is recognised as goodwill. Any unamortised balance of goodwill is included in the carrying value of the investment in associates.

 

Losses in excess of the carrying amount of an investment in an associate are recorded as a provision only when the company has incurred legal or constructive obligations or has made payments on behalf of the associate.

 

In the Company financial statements investments in associates are accounted for at cost less impairment.

1.8
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

 

The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.

Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment annually, and whenever there is an indication that the asset may be impaired.

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
1
Accounting policies
(Continued)
Page 25

Recoverable amount is the higher of fair value less costs to sell and value in use. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in surplus or deficit, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

 

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in surplus or deficit, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.9
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in surplus or deficit. Reversals of impairment losses are also recognised in surplus or deficit.

1.10
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of 100 days or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.11
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its financial instruments as Section 12 ‘Other Financial Instruments Issues’ is not relevant to the group.

 

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
1
Accounting policies
(Continued)
Page 26
Impairment of financial assets

Financial assets, other than those held at fair value through surplus or deficit, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in surplus or deficit.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in surplus or deficit.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.12
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable surplus for the year. Taxable surplus differs from net surplus as reported in the income and expenditure account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
1
Accounting policies
(Continued)
Page 27
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable surpluses. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax surplus nor the accounting surplus.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable surpluses will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income and expenditure account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.13
Provisions

Provisions are recognised when the group has a legal or constructive present obligation as a result of a past event, it is probable that the group will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

 

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation. Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value. When a provision is measured at present value, the unwinding of the discount is recognised as a finance cost in surplus or deficit in the period in which it arises.

1.14
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.15
Retirement benefits

Pension benefits for most employees of the company are provided by the NHS Pension Scheme, which is a statutory, unfunded, defined benefit scheme. The company’s liability is limited to the amount of contributions made to the scheme and liability for meeting pension payments sits solely with the scheme. For this reason the scheme is accounted for as if it were a defined contribution scheme. Accordingly company contributions are charged to surplus or deficit in the period to which they relate.

 

Employees that are not eligible to join the NHSPS are given the option to enrol in an alternative defined contribution scheme.

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
1
Accounting policies
(Continued)
Page 28
1.16
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the asset's fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to the income and expenditure account so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.

1.17
Merger Reserve

In a prior year the company merged with StourCare Community Interest Company and On Call Care Limited. The companies operated similar businesses to Integrated Care 24. The reserves were included in the merger reserve.

2
Judgements and key sources of estimation uncertainty

In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Useful economic life of tangible fixed assets

The annual depreciation charge for tangible fixed assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets.

Useful economic life of intangible fixed assets

The annual amortisation charge for intangible assets is sensitive to changes in the estimated lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually. Goodwill impairment reviews are also performed annually. These reviews require an estimation of the value in use of the cash generating units to which goodwill has been allocated. The value in use calculation requires the entity to estimate the future cash flows expected to arise for the cash generating unit and a suitable discount rate to calculate present value.

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
2
Judgements and key sources of estimation uncertainty
(Continued)
Page 29
Provisions for liabilities

On an ongoing basis the group assesses provisions that are required for liabilities as a result of past events. Provisions comprise estimated costs of insurance claims against the group ongoing at the year end and estimated costs of restoring office premises to its original condition at the termination of a lease. These are estimated with reference to the group insurance policies and industry expected restoration rates respectively.

3
Income

An analysis of the group's income is as follows:

2024
2023
£
£
Primary income
Provision of Out-of-Hours services
32,851,697
32,720,981
Provision of 111 and CAS services
32,327,487
31,081,080
Pharmacy income
1,409,060
2,737,340
GP practice income
3,323,803
1,218,642
Software income
833,868
638,945
Other income from associated services
4,225,241
4,636,718
74,971,156
73,033,706

Pharmacy income relates to the income of Pharma Alert 24 Limited, the subsidiary that was sold during the year (see note 14).

Other significant income
Interest income
843,222
384,115
Rental income
147,934
195,914
Income analysed by geographical market
2024
2023
£
£
United Kingdom
74,971,156
73,033,706
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 30
4
Operating surplus
2024
2023
£
£
Operating surplus for the year is stated after charging/(crediting):
Depreciation of owned tangible fixed assets
910,782
650,147
Depreciation of tangible fixed assets held under finance leases
7,843
66,122
Impairment of owned tangible fixed assets
-
5,470
Surplus on disposal of tangible fixed assets
(49,336)
(21,897)
Amortisation of intangible assets
144,830
215,035
Operating lease charges
1,777,564
1,495,723
5
Auditors' remuneration
2024
2023
Fees payable to the company's auditor and its associates:
£
£
For audit services
Audit of the financial statements of the group and company
29,600
29,000
Audit of the company's subsidiaries and associates
9,000
8,000
38,600
37,000
For other services
Accountancy services
13,000
11,000
Taxation compliance services
7,400
7,000
20,400
18,000
6
Employees

The average monthly number of persons (including directors) employed by the group during the year was:

2024
2023
Number
Number
Management
13
13
Operational
929
795
Administration
205
194
1,147
1,002
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
6
Employees
(Continued)
Page 31

Their aggregate remuneration comprised:

2024
2023
£
£
Wages and salaries
28,556,140
24,909,931
Social security costs
2,654,044
2,350,154
Pension costs
3,156,245
2,575,196
34,366,429
29,835,281
The majority of employee costs, save for directors remuneration (see note 7), is expensed to cost of sales in the statement of comprehensive income. Also within cost of sales are non-employed sessional GP costs including pension contributions and agency staff costs which total £27,600,591 (2023: £27,697,133).
7
Directors' remuneration
2024
2023
£
£
Remuneration for qualifying services
1,155,184
1,159,163
Company pension contributions
126,840
128,764
Compensation for loss of office
67,500
-
1,349,524
1,287,927
The number of directors for whom retirement benefits are accruing amounts to 8 (2023: 10).
Remuneration disclosed above (excluding termination payments) includes the following amounts paid to the highest paid director:
Remuneration for qualifying services
172,643
166,648
Company pension contributions
24,107
23,245

The directors are the group's key management personnel.

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 32
8
Interest receivable and similar income
2024
2023
£
£
Other interest receivable and similar income
Interest on bank deposits
810,230
384,115
Other interest income
32,992
-
Total interest revenue
843,222
384,115
Income from interest in associated undertakings
Share of profit from associate
118,302
121,317
Total interest and similar income
961,524
505,432
9
Interest payable and similar expenses
2024
2023
£
£
Interest on financial liabilities measured at amortised cost:
Other interest payable
-
134
Other finance costs:
Other interest
3,291
-
Total finance costs
3,291
134
10
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
309,932
834,187
Adjustments in respect of prior periods
(156,551)
(147,447)
Total current tax
153,381
686,740
Deferred tax
Origination and reversal of timing differences
119,686
142,441
Total tax charge
273,067
829,181
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
10
Taxation
(Continued)
Page 33

The charge for the year can be reconciled to the surplus per the income and expenditure account as follows:

2024
2023
£
£
Profit before taxation
1,315,914
4,977,986
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 25.00%)
328,979
1,244,497
Tax effect of expenses that are not deductible in determining taxable profit
23,078
(245)
Tax effect of income not taxable in determining taxable profit
(54,577)
921
Tax effect of utilisation of tax losses not previously recognised
-
0
(44,768)
Unutilised tax losses carried forward
-
0
30,842
Adjustments in respect of prior years
-
0
(147,447)
Dividend income
(25,000)
-
Surplus on disposal
(12,334)
(5,474)
Other differences
12,921
(65,827)
Effect of change in tax rates
-
(183,318)
Taxation charge
273,067
829,181
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 34
11
Intangible fixed assets
Group
Goodwill
Software
Development Costs
Total
£
£
£
£
Cost
At 1 July 2023
89,493
1,192,236
381,782
1,663,511
Additions
-
0
73,463
-
0
73,463
Disposals
(89,493)
-
0
-
0
(89,493)
At 30 June 2024
-
0
1,265,699
381,782
1,647,481
Amortisation and impairment
At 1 July 2023
89,493
914,465
381,782
1,385,740
Amortisation charged for the year
-
0
144,830
-
0
144,830
Disposals
(89,493)
-
0
-
0
(89,493)
At 30 June 2024
-
0
1,059,295
381,782
1,441,077
Carrying amount
At 30 June 2024
-
0
206,404
-
0
206,404
At 30 June 2023
-
0
277,771
-
0
277,771
Company
Software
Development Costs
Total
£
£
£
Cost
At 1 July 2023
1,166,079
381,782
1,547,861
Additions
73,463
-
0
73,463
At 30 June 2024
1,239,542
381,782
1,621,324
Amortisation and impairment
At 1 July 2023
903,733
381,782
1,285,515
Amortisation charged for the year
139,464
-
0
139,464
At 30 June 2024
1,043,197
381,782
1,424,979
Carrying amount
At 30 June 2024
196,345
-
0
196,345
At 30 June 2023
262,346
-
0
262,346

Development costs represent the development of the group's 111 and Out-of-Hours management and security software.

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 35
12
Tangible fixed assets
Group
Land and buildings Leasehold
Fixtures, fittings & equipment
Motor vehicles
Medical equipment
Total
£
£
£
£
£
Cost
At 1 July 2023
1,410,557
6,409,660
1,087,424
116,099
9,023,740
Additions
30,187
813,758
527,581
-
0
1,371,526
Disposals
(255,100)
(15,858)
(422,704)
-
0
(693,662)
Transfers
-
0
10,082
-
0
-
0
10,082
At 30 June 2024
1,185,644
7,217,642
1,192,301
116,099
9,711,686
Depreciation and impairment
At 1 July 2023
1,062,392
4,551,069
800,523
115,124
6,529,108
Depreciation charged in the year
159,469
628,578
129,603
975
918,625
Eliminated in respect of disposals
(255,100)
(15,857)
(422,704)
-
0
(693,661)
At 30 June 2024
966,761
5,163,790
507,422
116,099
6,754,072
Carrying amount
At 30 June 2024
218,883
2,053,852
684,879
-
0
2,957,614
At 30 June 2023
348,165
1,858,591
286,901
975
2,494,632
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
12
Tangible fixed assets
(Continued)
Page 36
Company
Land and buildings Leasehold
Fixtures, fittings & equipment
Motor vehicles
Medical equipment
Total
£
£
£
£
£
Cost
At 1 July 2023
1,132,429
6,453,481
1,087,003
111,094
8,784,007
Additions
30,187
812,521
527,581
-
0
1,370,289
Disposals
(36,561)
(27,455)
(422,704)
-
0
(486,720)
Transfers
-
0
10,082
-
0
-
0
10,082
At 30 June 2024
1,126,055
7,248,629
1,191,880
111,094
9,677,658
Depreciation and impairment
At 1 July 2023
784,264
4,608,682
800,102
110,119
6,303,167
Depreciation charged in the year
159,469
623,868
129,603
975
913,915
Eliminated in respect of disposals
(36,561)
(8,927)
(422,704)
-
0
(468,192)
At 30 June 2024
907,172
5,223,623
507,001
111,094
6,748,890
Carrying amount
At 30 June 2024
218,883
2,025,006
684,879
-
0
2,928,768
At 30 June 2023
348,165
1,844,799
286,901
975
2,480,840

The net carrying value of tangible fixed assets in both the group and the company includes the following in respect of assets held under finance leases or hire purchase contracts. The depreciation charge in respect of such assets amounted to £7,843 (2023: £66,122). Assets purchased in the period under finance lease or hire purchase contracts amounted to £nil (2023: £nil).

Group
Company
2024
2023
2024
2023
£
£
£
£
Fixtures, fittings & equipment
-
0
7,843
-
0
7,843
13
Fixed asset investments
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Investments in subsidiaries
14
-
0
-
0
120
120
Investments in associates
15
177,931
159,629
500
500
177,931
159,629
620
620
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
13
Fixed asset investments
(Continued)
Page 37
Movements in fixed asset investments
Group
Shares
£
Cost or valuation
At 1 July 2023
159,629
Share of profit in year
118,302
Dividends received
(100,000)
At 30 June 2024
177,931
Carrying amount
At 30 June 2024
177,931
At 30 June 2023
159,629
Movements in fixed asset investments
Company
Shares
£
Cost or valuation
At 1 July 2023 and 30 June 2024
620
Carrying amount
At 30 June 2024
620
At 30 June 2023
620
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 38
14
Subsidiaries

Details of the company's subsidiaries at 30 June 2024 are as follows:

Name of undertaking
Country of
Class of
% Shares
Incorporation
shareholding
held
Brightdoc 24 Limited
England & Wales
Ordinary
100
Cleo Systems 24 Limited
England & Wales
Ordinary
100
Name of undertaking
Nature of business
Brightdoc 24 Limited
Supply of locum doctors
Cleo Systems 24 Limited
Development and integration of digital solutions for healthcare services

The companies above all have their registered office at Kingston House, The Long Barrow, Orbital Park, Ashford, Kent, TN24 0GP.

 

On 8 February 2024, the company disposed of its subsidiary, Pharma Alert 24 Limited.

 

Disposals

 

 

 

 

 

 

 

 

 

 

£

Net assets

 

 

100,795

Gain on disposal

 

 

200,000

Total consideration

 

 

───────

 

 

 

300,795

The consideration was satisfied by:

 

 

═══════

 

 

 

 

 

 

 

£

Cash

Outstanding consideration due to be paid 2025

 

 

200,000

100,795

 

 

 

 

 

 

 

 

 

 

 

 

 

 

£

 

 

 

100,795

 

 

 

200,000

 

 

 

───────

 

 

 

300,795

 

 

 

═══════

 

 

 

 

 

 

 

£

 

 

 

300,795

 

 

 

═══════

 

 

 

═══════

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 39
15
Associates

Details of the company's associates at 30 June 2024 are as follows:

Name of undertaking
Country of
Class of
% Shares
Incorporation
shareholding
Held
iDental Care 24 Limited
England & Wales
A Ordinary
50
Name of undertaking
Nature of business
iDental Care 24 Limited
Out of hours dental provider

iDental Care 24 Limited has its registered office at Kingston House, The Long Barrow, Orbital Park, Ashford, Kent, TN24 0GP.

16
Stocks
Group
Company
2024
2023
2024
2023
£
£
£
£
Finished goods and goods for resale
-
0
104,168
-
0
-
0

All stock in the prior year related to Pharma Alert 24 Limited, the subsidiary disposed of during the current year.

17
Debtors
Group
Company
2024
2023
2024
2023
Amounts falling due within one year:
£
£
£
£
Trade debtors
2,821,655
8,432,300
2,634,017
7,907,010
Corporation tax recoverable
310,786
25,466
310,786
25,466
Amounts owed by group undertakings
-
-
1,033,791
765,838
Other debtors
144,926
89,897
144,926
11,104
Prepayments and accrued income
3,053,679
2,711,898
2,991,837
2,681,259
6,331,046
11,259,561
7,115,357
11,390,677
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 40
18
Creditors: amounts falling due within one year
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Obligations under finance leases
20
-
0
29,643
-
0
29,643
Other taxation and social security
1,591,179
1,729,120
1,488,543
1,657,758
Trade creditors
1,768,356
2,609,108
1,738,724
2,251,406
Amounts due to subsidiary undertakings
-
0
-
0
1,157,527
1,252,028
Other creditors
36,701
90,984
23,838
20,619
Accruals and deferred income
4,471,881
4,852,102
3,160,639
4,152,841
7,868,117
9,310,957
7,569,271
9,364,295
19
Creditors: amounts falling due after more than one year
Group
Company
2024
2023
2024
2023
£
£
£
£
Accruals and deferred income
27,487
129,162
27,487
129,162
20
Finance lease obligations
Group
Company
2024
2023
2024
2023
£
£
£
£
Future minimum lease payments due under finance leases:
Within one year
-
0
29,643
-
0
29,643
21
Provisions for liabilities
Group
Company
2024
2023
2024
2023
£
£
£
£
Other provisions
241,667
385,899
241,667
385,899
Dilapidations provisions
386,492
378,580
386,492
378,580
628,159
764,479
628,159
764,479
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
21
Provisions for liabilities
(Continued)
Page 41
Movements on provisions:
Other provisions
Dilapidations provisions
Total
Group
£
£
£
Net movement in provisions in the year
(144,232)
7,912
(136,320)
Other provisions
Dilapidations provisions
Total
Company
£
£
£
Net movement in provisions in the year
(144,232)
7,912
(136,320)

Other provisions is comprised of the estimated costs of insurance claims against the group ongoing at the year end as well as the estimated cost of staff who will deal with these claims.

22
Contingent liabilities

From April 2019, following the launch of the Clinical Negligence Scheme for General Practice (CNSGP), the company has not needed to fund its own clinical negligence insurance cover as this is provided by the new state-backed scheme.

 

The company does, however, have liability for claims brought after April 2019 for medical incidents occurring prior to this date. In September 2024 the company purchased clinical negligence cover for the 12 months to September 2025 for £381,800 to cover claims brought in this period relating to medical incidents prior to April 2019.

 

The company has also made a provision of £200,000 (2023: £210,000) for potential future claims made under the Human Rights Act relating to the termination of the Health and Justice Contract in the year. This provision is included within note 21. This is the best estimate of the Directors of any potential further liability relating to this contract based on the evidence they have available but note that there may be future claims which will require settlement for amounts beyond the provision already made within these financial statements.

Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 42
23
Deferred taxation

Deferred tax assets and liabilities are offset where the group or company has a legally enforceable right to do so. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:

Liabilities
Liabilities
2024
2023
Group
£
£
Accelerated capital allowances
453,487
322,133
Other timing differences
(128,376)
(116,708)
325,111
205,425
Liabilities
Liabilities
2024
2023
Company
£
£
Accelerated capital allowances
453,487
322,133
Other timing differences
(128,376)
(116,708)
325,111
205,425
Group
Company
2024
2024
Movements in the year:
£
£
Liability at 1 July 2023
205,425
205,425
Charge to profit or loss
119,686
119,686
Liability at 30 June 2024
325,111
325,111
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 43
24
Retirement benefit schemes
2024
2023
£
£
Charge to surplus or deficit in respect of defined benefit schemes
3,061,810
2,500,147
Charge to surplus or deficit in respect of defined contribution schemes
94,434
75,048
Contributions payable to funds at the year end included in creditors
403,338
418,358

The NHS Pension Scheme, which is a defined benefit scheme, is available for all qualifying employees. As the company’s liability is limited to the amount of contributions made to the scheme, it is accounted for as if it were a defined contribution scheme.

25
Operating lease commitments
Lessee

At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Group
Company
2024
2023
2024
2023
£
£
£
£
Within one year
663,966
684,745
663,966
684,745
Between two and five years
310,146
845,026
310,146
845,026
974,112
1,529,771
974,112
1,529,771
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 44
26
Related party transactions

Group

The group has taken advantage of the exemption within FRS 102 Section 33.1A Related Party Disclosures to not disclose transactions with entities that are within the same group and included in the consolidated financial statements of the group.

 

Company

During the year the company charged a management fee of £12,226 (2023: £12,226) to its associate iDental Care 24 Limited. The outstanding balance at the year end was £nil (2023: £95).

 

During the year £532,273 was invoiced in relation to GP practice services provided to Transforming Primary Care Limited, a company related by virtue of there being common directors. This amount was settled in full during the year and there were no amounts outstanding at the balance sheet date.

27
Cash generated from group operations
2024
2023
£
£
Surplus for the year after tax
1,042,847
4,148,805
Adjustments for:
Taxation charged
273,067
829,181
Finance costs
3,291
134
Investment income
(961,524)
(505,432)
Gain on disposal of tangible fixed assets
(49,336)
(21,897)
Amortisation and impairment of intangible assets
144,830
215,035
Depreciation and impairment of tangible fixed assets
918,625
721,739
Profit on disposal of subsidiary
(200,000)
-
Decrease in provisions
(136,320)
(261,706)
Movements in working capital:
Decrease/(increase) in stocks
104,168
(8,723)
Decrease/(increase) in debtors
5,191,676
(1,487,536)
(Decrease)/increase in creditors
(2,330,750)
637,342
Increase/(decrease) in deferred income
819,169
(122,006)
Cash generated from operations
4,819,743
4,144,936
28
Analysis of changes in net funds - group
1 July 2023
Cash flows
30 June 2024
£
£
£
Cash at bank and in hand
16,675,307
4,104,464
20,779,771
Obligations under finance leases
(29,643)
29,643
-
16,645,664
4,134,107
20,779,771
Integrated Care 24
Notes to the Financial Statements (Continued)
For the year ended 30 June 2024
Page 45
29
Subsidiary audit exemption

The company’s active subsidiary, Brightdoc 24 Limited is exempt from the requirements of the Companies Act 2006 relating to the audit of their individual accounts by virtue of section 479A of the Companies Act 2006.

 

The parent company has therefore guaranteed all existing liabilities of the above entity and this guarantee will remain in force until those liabilities are settled.

2024-06-302023-07-01falsefalseCCH SoftwareCCH Accounts Production 2024.301No description of principal activityA CattoA KarkiA OagD BrownD R BainesK GentlemanK PittsP BrookeR RobinsonS P KingD L SuppleK EldridgeR T McEwanfalse031931822023-07-012024-06-3003193182bus:Director12023-07-012024-06-3003193182bus:Director22023-07-012024-06-3003193182bus:Director32023-07-012024-06-3003193182bus:Director42023-07-012024-06-3003193182bus:Director52023-07-012024-06-3003193182bus:Director62023-07-012024-06-3003193182bus:Director72023-07-012024-06-3003193182bus:Director82023-07-012024-06-3003193182bus:Director92023-07-012024-06-3003193182bus:Director102023-07-012024-06-3003193182bus:Director112023-07-012024-06-3003193182bus:Director122023-07-012024-06-3003193182bus:Director132023-07-012024-06-3003193182bus:RegisteredOffice2023-07-012024-06-30031931822024-06-3003193182bus:Consolidated2023-07-012024-06-3003193182bus:Consolidated2022-07-012023-06-30031931822022-07-012023-06-3003193182bus:Consolidated2024-06-3003193182core:OtherResidualIntangibleAssetsbus:Consolidated2024-06-3003193182core:OtherResidualIntangibleAssetsbus:Consolidated2023-06-3003193182core:OtherResidualIntangibleAssets2024-06-3003193182core:OtherResidualIntangibleAssets2023-06-3003193182core:NetGoodwill2023-06-3003193182core:Goodwillbus:Consolidated2024-06-3003193182core:ComputerSoftwarebus:Consolidated2024-06-3003193182core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2024-06-3003193182core:Goodwillbus:Consolidated2023-06-3003193182core:ComputerSoftwarebus:Consolidated2023-06-3003193182core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2023-06-3003193182bus:Consolidated2023-06-3003193182core:ComputerSoftware2024-06-3003193182core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-06-3003193182core:ComputerSoftware2023-06-3003193182core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-06-30031931822023-06-3003193182core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-06-3003193182core:FurnitureFittingsbus:Consolidated2024-06-3003193182core:MotorVehiclesbus:Consolidated2024-06-3003193182core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2024-06-3003193182core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2023-06-3003193182core:FurnitureFittingsbus:Consolidated2023-06-3003193182core:MotorVehiclesbus:Consolidated2023-06-3003193182core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2023-06-3003193182core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-06-3003193182core:FurnitureFittings2024-06-3003193182core:MotorVehicles2024-06-3003193182core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-06-3003193182core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-06-3003193182core:FurnitureFittings2023-06-3003193182core:MotorVehicles2023-06-3003193182core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2023-06-3003193182core:CurrentFinancialInstrumentscore:WithinOneYear2024-06-3003193182core:CurrentFinancialInstrumentscore:WithinOneYear2023-06-3003193182core:Non-currentFinancialInstrumentscore:AfterOneYear2024-06-3003193182core:Non-currentFinancialInstrumentscore:AfterOneYear2023-06-3003193182core:CurrentFinancialInstruments2024-06-3003193182core:CurrentFinancialInstruments2023-06-3003193182core:Non-currentFinancialInstruments2024-06-3003193182core:Non-currentFinancialInstruments2023-06-3003193182core:OtherMiscellaneousReservebus:Consolidated2024-06-3003193182core:OtherMiscellaneousReservebus:Consolidated2023-06-3003193182core:OtherMiscellaneousReserve2024-06-3003193182core:OtherMiscellaneousReserve2023-06-3003193182core:RetainedEarningsAccumulatedLosses2024-06-3003193182core:RetainedEarningsAccumulatedLosses2023-06-3003193182core:OtherMiscellaneousReserve2022-06-3003193182core:RetainedEarningsAccumulatedLosses2022-06-30031931822022-06-3003193182bus:Consolidated2022-06-3003193182core:IntangibleAssetsOtherThanGoodwill2023-07-012024-06-3003193182core:LandBuildingscore:LongLeaseholdAssets2023-07-012024-06-3003193182core:FurnitureFittings2023-07-012024-06-3003193182core:MotorVehicles2023-07-012024-06-3003193182core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2023-07-012024-06-3003193182core:UKTaxbus:Consolidated2023-07-012024-06-3003193182core:UKTaxbus:Consolidated2022-07-012023-06-3003193182bus:Consolidated12023-07-012024-06-3003193182bus:Consolidated12022-07-012023-06-3003193182bus:Consolidated22023-07-012024-06-3003193182bus:Consolidated22022-07-012023-06-3003193182core:Goodwillbus:Consolidated2023-06-3003193182core:ComputerSoftwarebus:Consolidated2023-06-3003193182core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2023-06-3003193182bus:Consolidated2023-06-3003193182core:ComputerSoftware2023-06-3003193182core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-06-30031931822023-06-3003193182core:Goodwillcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2023-07-012024-06-3003193182core:ComputerSoftwarecore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2023-07-012024-06-3003193182core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2023-07-012024-06-3003193182core:ExternallyAcquiredIntangibleAssetsbus:Consolidated2023-07-012024-06-3003193182core:ComputerSoftwarecore:ExternallyAcquiredIntangibleAssets2023-07-012024-06-3003193182core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:ExternallyAcquiredIntangibleAssets2023-07-012024-06-3003193182core:ExternallyAcquiredIntangibleAssets2023-07-012024-06-3003193182core:Goodwillbus:Consolidated2023-07-012024-06-3003193182core:ComputerSoftwarebus:Consolidated2023-07-012024-06-3003193182core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2023-07-012024-06-3003193182core:ComputerSoftware2023-07-012024-06-3003193182core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-07-012024-06-3003193182core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2023-06-3003193182core:FurnitureFittingsbus:Consolidated2023-06-3003193182core:MotorVehiclesbus:Consolidated2023-06-3003193182core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2023-06-3003193182core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-06-3003193182core:FurnitureFittings2023-06-3003193182core:MotorVehicles2023-06-3003193182core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2023-06-3003193182core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2023-07-012024-06-3003193182core:FurnitureFittingsbus:Consolidated2023-07-012024-06-3003193182core:MotorVehiclesbus:Consolidated2023-07-012024-06-3003193182core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2023-07-012024-06-3003193182core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-07-012024-06-3003193182core:ComputerEquipmentbus:Consolidated2024-06-3003193182core:ComputerEquipmentbus:Consolidated2023-06-3003193182core:ComputerEquipment2024-06-3003193182core:ComputerEquipment2023-06-3003193182core:Subsidiary12023-07-012024-06-3003193182core:Subsidiary22023-07-012024-06-3003193182core:CurrentFinancialInstrumentsbus:Consolidated2024-06-3003193182core:CurrentFinancialInstrumentsbus:Consolidated2023-06-3003193182core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-06-3003193182core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2023-06-3003193182core:Non-currentFinancialInstrumentsbus:Consolidated2024-06-3003193182core:Non-currentFinancialInstrumentsbus:Consolidated2023-06-3003193182core:WithinOneYearbus:Consolidated2024-06-3003193182core:WithinOneYearbus:Consolidated2023-06-3003193182core:WithinOneYear2024-06-3003193182core:WithinOneYear2023-06-3003193182bus:PrivateLimitedCompanyLtd2023-07-012024-06-3003193182bus:FRS1022023-07-012024-06-3003193182bus:Audited2023-07-012024-06-3003193182bus:ConsolidatedGroupCompanyAccounts2023-07-012024-06-3003193182bus:FullAccounts2023-07-012024-06-30xbrli:purexbrli:sharesiso4217:GBP